| Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization EH Kim, JA Bird, M Kulis, S Laubach, L Pons, W Shreffler, P Steele, ... Journal of Allergy and Clinical Immunology 127 (3), 640-646. e1, 2011 | 440 | 2011 |
| Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective BP Vickery, JP Berglund, CM Burk, JP Fine, EH Kim, JI Kim, CA Keet, ... Journal of Allergy and Clinical Immunology 139 (1), 173-181. e8, 2017 | 353 | 2017 |
| Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial DM Fleischer, M Greenhawt, G Sussman, P Bégin, A Nowak-Wegrzyn, ... Jama 321 (10), 946-955, 2019 | 247 | 2019 |
| Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial JA Bird, JM Spergel, SM Jones, R Rachid, AH Assa'ad, J Wang, ... The Journal of Allergy and Clinical Immunology: In Practice 6 (2), 476-485. e3, 2018 | 179 | 2018 |
| Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study SM Jones, EH Kim, KC Nadeau, A Nowak-Wegrzyn, RA Wood, ... The Lancet 399 (10322), 359-371, 2022 | 165 | 2022 |
| Long-term sublingual immunotherapy for peanut allergy in children: clinical and immunologic evidence of desensitization EH Kim, L Yang, P Ye, R Guo, Q Li, MD Kulis, AW Burks Journal of Allergy and Clinical Immunology 144 (5), 1320-1326. e1, 2019 | 117 | 2019 |
| Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy M Kulis, K Saba, EH Kim, JA Bird, N Kamilaris, BP Vickery, H Staats, ... Journal of Allergy and Clinical Immunology 129 (4), 1159-1162, 2012 | 113 | 2012 |
| Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison SJ Chin, BP Vickery, MD Kulis, EH Kim, P Varshney, P Steele, J Kamilaris, ... Journal of allergy and clinical immunology 132 (2), 476-478. e2, 2013 | 105 | 2013 |
| Clinical characteristics of peanut-allergic children: recent changes TD Green, VS LaBelle, PH Steele, EH Kim, LA Lee, VS Mankad, ... Pediatrics 120 (6), 1304-1310, 2007 | 101 | 2007 |
| Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results DM Fleischer, WG Shreffler, DE Campbell, TD Green, S Anvari, A Assa’ad, ... Journal of Allergy and Clinical Immunology 146 (4), 863-874, 2020 | 77 | 2020 |
| Food allergy immunotherapy: oral immunotherapy and epicutaneous immunotherapy EH Kim, AW Burks Allergy 75 (6), 1337-1346, 2020 | 77 | 2020 |
| Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study BP Vickery, A Vereda, C Nilsson, G du Toit, WG Shreffler, AW Burks, ... The Journal of Allergy and Clinical Immunology: In Practice 9 (5), 1879-1889 …, 2021 | 66 | 2021 |
| Immunoglobulin variable-region diversity in the zebrafish N Danilova, VS Hohman, EH Kim, LA Steiner Immunogenetics 52, 81-91, 2000 | 66 | 2000 |
| Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy EH Kim, TT Perry, RA Wood, DYM Leung, MC Berin, AW Burks, CB Cho, ... Journal of Allergy and Clinical Immunology 146 (4), 851-862. e10, 2020 | 60 | 2020 |
| Mechanisms of oral immunotherapy SM Barshow, MD Kulis, AW Burks, EH Kim Clinical & Experimental Allergy 51 (4), 527-535, 2021 | 51 | 2021 |
| Phase 3 trial of epicutaneous immunotherapy in toddlers with peanut allergy M Greenhawt, SB Sindher, J Wang, M O’Sullivan, G Du Toit, EH Kim, ... New England Journal of Medicine 388 (19), 1755-1766, 2023 | 50 | 2023 |
| High‐and low‐dose oral immunotherapy similarly suppress pro‐allergic cytokines and basophil activation in young children M Kulis, X Yue, R Guo, H Zhang, K Orgel, P Ye, Q Li, Y Liu, E Kim, ... Clinical & Experimental Allergy 49 (2), 180-189, 2019 | 50 | 2019 |
| Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies M Greenhawt, M Shaker, T Winders, DA Bukstein, RS Davis, ... Annals of Allergy, Asthma & Immunology 125 (1), 90-96, 2020 | 40 | 2020 |
| Safety of epicutaneous immunotherapy in peanut-allergic children: REALISE randomized clinical trial results JA Pongracic, R Gagnon, G Sussman, D Siri, RC Oriel, ... The Journal of Allergy and Clinical Immunology: In Practice 10 (7), 1864 …, 2022 | 39 | 2022 |
| Omalizumab for the treatment of multiple food allergies RA Wood, A Togias, SH Sicherer, WG Shreffler, EH Kim, SM Jones, ... New England Journal of Medicine 390 (10), 889-899, 2024 | 38 | 2024 |
